ABO gene polymorphisms dictate susceptibility to cancers, cardiovascular, and infectious diseases, influencing drug efficacy.
Background
Beyond their role as red blood cell surface markers, ABO gene polymorphisms are critical genetic determinants influencing disease susceptibility and drug response. Current understanding highlights a gap in leveraging these genetic variations for personalized medicine. The ABO gene encodes glycosyltransferases with distinct structures, leading to differential risks for various conditions. Its influence extends to critical pathophysiological pathways, including coagulation, inflammation, and cellular signaling, making it a key factor in disease pathogenesis.
Study Design
This umbrella review synthesized evidence from multiple systematic reviews and meta-analyses to investigate the association between ABO gene polymorphisms and disease risk, as well as therapeutic outcomes. The authors compiled and analyzed existing epidemiological data and functional studies, focusing on how variations in ABO glycosyltransferases contribute to differential susceptibility across various disease categories. The methodology involved a comprehensive synthesis of findings from numerous prior reviews, aiming to establish a molecular bridge between genetic variations in ABO and clinical implications.
Results
ABO gene polymorphisms profoundly influence disease susceptibility and drug efficacy. Epidemiological data consistently link non-O blood groups with a heightened incidence of several cancers, including gastric, pancreatic, ovarian, and bladder cancers. Individuals with non-O blood groups also exhibit higher concentrations of von Willebrand factor (vWF), predisposing them to atherosclerosis, thrombosis, and ischemic heart disease. This contrasts with group O individuals, who demonstrate a greater likelihood of contracting gastrointestinal infections, notably from Helicobacter pylori, noroviruses, and Vibrio cholerae, often experiencing more severe symptoms.
Functional variations in
ABO glycosyltransferasesdirectly modulate drug efficacy, indicating a significant role in pharmacogenomics.
Key Findings
- Non-O blood groups are linked to higher incidence of gastric, pancreatic, ovarian, and bladder cancers.
- Non-O blood groups show elevated von Willebrand factor (vWF), increasing risk for atherosclerosis and thrombosis.
- Group O individuals have higher susceptibility to severe gastrointestinal infections (e.g., H. pylori, noroviruses).
- Functional variations in ABO glycosyltransferases directly modulate drug efficacy.
- ABO blood typing holds promise for personalized disease risk prediction and treatment strategies.
Why It Matters
Understanding ABO gene polymorphisms offers a powerful tool for advancing personalized medicine, moving beyond generalized treatment approaches. This review highlights that blood type isn't just for transfusions; it's a critical predictor of disease risk and drug response. For clinicians and biohackers, this means that ABO blood typing could inform personalized prevention strategies and optimize therapeutic protocols for conditions like cancer, cardiovascular disease, and infectious diseases. While not a direct protocol, it suggests that future stacks or treatment plans might incorporate ABO status to tailor interventions, potentially improving efficacy and reducing adverse effects by predicting individual responses based on genetic predispositions. Further research is needed to translate these associations into actionable clinical guidelines.
abo-gene
polymorphisms
disease-susceptibility
drug-response
cancer
cardiovascular-disease